Skip to content
Clinical Trials – home

Azienda Ospedaliera Universitaria Meyer IRCCS

Research site

Italy Viale Gaetano Pieraccini 24, 50139 Florence, Italy

  • 59 trials recruiting
  • Cystic fibrosis · Juvenile idiopathic arthritis · Colitis ulcerative
  • Adults and children

About Specializations

Azienda Ospedaliera Universitaria Meyer IRCCS in Florence, Italy specialises in clinical trials of conditions such as Cystic fibrosis, Juvenile idiopathic arthritis, Colitis ulcerative, Migraine, and other specialisations. This site conducts important research.

Main research areas of the site

Gastroenterology and Nutrition Research

At Azienda Ospedaliera Universitaria Meyer IRCCS in Florence, clinical research in Gastroenterologia e Nutrizione focuses strongly on digestive system diseases, especially Crohn’s disease, ulcerative colitis, and broader inflammatory bowel disease. The trials are designed to improve treatment effectiveness, refine long-term disease control, and support more personalized care for children and adolescents.

  • Testing newer therapies for Crohn’s disease and ulcerative colitis
  • Evaluating strategies to improve symptom control and reduce disease flares in inflammatory bowel disease
  • Studying treatment durability and safety in pediatric gastrointestinal care

The site’s work also extends to nutritional and metabolic diseases, reflecting the close connection between digestion, growth, and overall pediatric health.

Pediatric Immunology and Rheumatology

A major part of the research portfolio at this site covers immune system diseases and musculoskeletal diseases, with a strong emphasis on juvenile idiopathic arthritis, juvenile psoriatic arthritis, and uveitis. These studies aim to compare treatment approaches, improve disease control, and help clinicians tailor therapy more precisely for young patients.

  • Comparing treatment approaches in juvenile idiopathic arthritis
  • Studying biologic therapies for juvenile psoriatic arthritis and related conditions
  • Assessing better ways to manage uveitis linked to pediatric inflammatory disease

This research supports safer long-term management of chronic inflammatory conditions in children and adolescents.

Pediatric Oncology and Hematology

The research landscape includes extensive work in neoplasms, hemic and lymphatic diseases, and genetic phenomena, with trials involving acute lymphoblastic leukemia, Hodgkin lymphoma, medulloblastoma, and other childhood cancers. The main goal is to improve survival, reduce relapse risk, and optimize treatment for young patients with high-risk or relapsed disease.

  • Evaluating new treatment combinations for acute lymphoblastic leukemia and lymphoblastic lymphoma
  • Studying better strategies for Hodgkin lymphoma, neuroblastoma, and rhabdomyosarcoma
  • Testing approaches to improve outcomes in medulloblastoma, ependymoma, and low-grade glioma

These trials reflect a strong pediatric cancer program at Azienda Ospedaliera Universitaria Meyer IRCCS, with an emphasis on more effective and individualized care.

Neurology, Epilepsy, and Migraine

Research in nervous system diseases includes studies of developmental and epileptic encephalopathies, Dravet syndrome, Lennox-Gastaut syndrome, refractory focal onset epilepsy, and migraine. The trials are focused on finding better seizure control, easing headache burden, and improving day-to-day functioning for children and adolescents.

  • Testing new options for difficult-to-control epilepsy syndromes
  • Evaluating preventive and symptomatic treatments for migraine
  • Exploring therapies for rare neurodevelopmental disorders

This area combines symptom relief with longer-term safety and quality-of-life goals.

Respiratory, Infectious, and Cystic Fibrosis Studies

The site also conducts trials in respiratory tract diseases, bacterial infections, and virus diseases, including cystic fibrosis, bronchiectasis, influenza, sepsis, and serious hospital-acquired infections. These studies aim to improve infection control, lung function, and treatment outcomes in vulnerable pediatric patients.

  • Assessing new therapies for cystic fibrosis and related lung disease
  • Studying better management of severe infections in hospitalized children
  • Evaluating ways to support respiratory health in chronic pediatric disease

The research combines practical infection management with long-term respiratory care.

Endocrine, Growth, and Metabolic Disorders

Another important focus is hormonal diseases and nutritional and metabolic diseases, with studies in growth hormone deficiency, short stature, obesity, type 1 diabetes, and rare metabolic conditions. The purpose is to improve growth, metabolic balance, and long-term health outcomes in children.

  • Evaluating treatments for growth disorders and short stature
  • Studying care approaches for obesity and diabetes
  • Investigating therapies for rare metabolic diseases

These trials support earlier intervention and more individualized pediatric endocrine care.

Cardiology, Kidney, and Rare Disease Research

Clinical research at the Florence site also includes cardiovascular diseases and kidney disease, such as heart failure, hypertrophic cardiomyopathy, chronic kidney disease, and proteinuria. In parallel, the program covers several rare genetic disorders, aiming to improve safety, disease control, and long-term outcomes.

  • Testing new approaches for heart failure and hypertrophic cardiomyopathy
  • Evaluating treatments for chronic kidney disease and proteinuria
  • Studying therapies for rare inherited conditions and complex pediatric syndromes

This work highlights a broad commitment to both common chronic illnesses and uncommon diseases requiring specialized care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Viale Gaetano Pieraccini 2450139 FlorenceItaly
Recruiting now
59 trials
Conditions studied
104

More sites in FlorenceItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

137 clinical trials

Obesity+1

Recruiting

Study on the Effectiveness and Safety of Orforglipron for Weight Management in Adolescents with Obesity or Overweight

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

A Study of Baricitinib to Delay Type 1 Diabetes in Children and Adults at Risk of Developing the Disease

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Phase 3 Study of Oral Orforglipron vs Weekly Dulaglutide in Children and Adolescents (10‑<18 years) with Type 2 Diabetes

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.

Treatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Arsenic Trioxide
  • Sponsor:Associazione Italiana Ematologia Oncologia Pediatrica

A study to evaluate the efficacy and safety of rilzabrutinib in adults with active IgG4-related disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study to evaluate the effectiveness and safety of clemizole hydrochloride as an additional treatment for patients with Lennox-Gastaut syndrome

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Clemizole Hydrochloride
  • Sponsor:Epygenix Therapeutics Inc.

Rett syndrome

Recruiting

A Phase 3 Study of Fenfluramine Hydrochloride for Safety and Efficacy in Patients with Rett Syndrome

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Fenfluramine Hydrochloride
  • Sponsor:UCB Biosciences Inc.

A study to evaluate the safety and effectiveness of filgotinib in children and adolescents aged 8 to 17 years with polyarticular juvenile idiopathic arthritis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

A study to evaluate the efficacy and safety of etrasimod arginine in children with moderately to severely active ulcerative colitis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Etrasimod Arginine
  • Sponsor:Pfizer Inc.

Short stature+1

Recruiting

Study of Lonapegsomatrin and Somatropin in Children and Adolescents with Short Stature or Growth Failure due to Turner Syndrome, SHOX Deficiency, SGA, or Idiopathic Short Stature

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Lonapegsomatropin
  • Sponsor:Ascendis Pharma Endocrinology Division A/S
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.